



Am dt  
10/A  
henda  
8/30/01

EXPRESS MAIL NO.: EL 168 272 557 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: SCHNEIDER AND JAMAL

Application No.: 09/305,084

Group Art Unit: 1642

AUG 29 2001

Filed: May 4, 1999

Examiner: A. Harris

TECH CENTER 1600/2900

For: **CANCER TREATMENT WITH ENDOTHELIN RECEPTOR ANTAGONISTS** Attorney Docket No.: 5914-080-999

RECEIVED

**AMENDMENT UNDER 37 C.F.R. § 1.111**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

In response to the outstanding Office Action mailed February 23, 2001, please enter the following amendments and consider the remarks made below in connection with the above-identified application. Also submitted concurrently are: (a) a Petition to Extend Time accompanied by the required fee; (b) a marked-up version of the paragraph amended herein as Appendix A; (c) a marked-up version of the claims amended herein as Appendix B; (d) a clean copy of the claims as pending in the present application after entry of the present amendment as Appendix C; (e) replacement informal Figures 1-4 as Appendix D; (f) Egidy et al., 2000, *Lab Invest* 80:1681-9, submitted herewith as Exhibit 1; and (g) Alanen et al., 2000, *Histopatholog* 36:161, submitted herewith as Exhibit 2.

**IN THE SPECIFICATION**

Please amend the specification to read as follows:

On page 19, please replace the third full paragraph with the following: